Your browser doesn't support javascript.
loading
Exploring metabolically healthy obesity: prevalence, characteristics, and cardiovascular risk in the Iranian population based on the STEPS 2021.
Langroudi, Ashkan Pourabhari; Farzi, Yosef; Masinaei, Masoud; Varniab, Zahra Shokri; Shahin, Sarvenaz; Rashidi, Mohammad-Mahdi; Moghaddam, Sahar Saeedi; Rahimi, Shakiba; Khalili, Majid; Keykhaei, Mohammad; Ahmadi, Naser; Kazemi, Ameneh; Ghasemi, Erfan; Azadnajafabad, Sina; Yoosefi, Moein; Fattahi, Nima; Nasserinejad, Maryam; Rezaei, Nazila; Haghshenas, Rosa; Dilmaghani-Marand, Arezou; Abdolhamidi, Elham; Djalalinia, Shirin; Rezaei, Negar; Larijani, Bagher; Farzadfar, Farshad.
Afiliação
  • Langroudi AP; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Farzi Y; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Masinaei M; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Varniab ZS; Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
  • Shahin S; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Rashidi MM; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Moghaddam SS; Department of Pediatrics, New York University Grossman School of Medicine, New York, NY USA.
  • Rahimi S; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Khalili M; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Keykhaei M; Kiel Institute for the World Economy, Kiel, Germany.
  • Ahmadi N; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Kazemi A; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Ghasemi E; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Azadnajafabad S; Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD USA.
  • Yoosefi M; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Fattahi N; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Nasserinejad M; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Rezaei N; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Haghshenas R; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Dilmaghani-Marand A; Department of Mathematics and Statistics, Memorial University of Newfoundland, St. John's, NL Canada.
  • Abdolhamidi E; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Djalalinia S; Department of Internal Medicine, Yale School of Medicine, New Haven, CT USA.
  • Rezaei N; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Larijani B; Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
  • Farzadfar F; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord ; 23(1): 881-893, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38932890
ABSTRACT

Background:

Regarding the rapidly increasing prevalence of obesity throughout the globe, it remains a serious public health concern. A subgroup of obesity that does not meet metabolic syndrome criteria is called metabolically healthy obesity (MHO). However, whether the MHO phenotype increases cardiovascular disease (CVD) risk is controversial. This study aimed to evaluate the prevalence of MHO and its 10-year CVD risk in Iranian populations.

Methods:

Based on the STEPS 2021 project in Iran, we collected data on 18119 Iranians 25 years and older from all 31 provinces after applying many statistical factors. Using the Framingham score, we evaluated the 10-year cardiovascular risk associated with the various MHO definition criteria for Iranian populations.

Results:

The prevalence of MHO was 6.42% (5.93-6.91) at the national level according to the AHA-NHLBI definition, and 23.29% of obese women and 24.55% of obese men were classified as MHOs. Moreover, the MHO group was younger than the metabolically unhealthy obesity (MUO) group based on all definitions (p < 0.001). The odds ratio of MUO individuals being classified as high-risk individuals by the Framingham criteria for CVD was significantly higher than that of MHO individuals by all definitions, with a crude odds ratio of 3.551 based on AHA-NHLBI definition.

Conclusion:

This study reveals a significant prevalence of MHO in the Iranian population, with approximately 25% of obese individuals classified as MHO. While MHO is associated with a lower risk of cardiovascular disease compared to MUO, MHO carries the potential for transitioning to an unhealthy state. Supplementary Information The online version contains supplementary material available at 10.1007/s40200-023-01364-5.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Diabetes Metab Disord Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Diabetes Metab Disord Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Irã